Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study).
Borghaei H, Redman MW, Kelly K, Waqar SN, Robert F, Kiefer GJ, Stella PJ, Minichiello K, Gandara DR, Herbst RS, Papadimitrakopoulou VA. Borghaei H, et al. Clin Lung Cancer. 2021 May;22(3):178-186. doi: 10.1016/j.cllc.2020.10.015. Epub 2020 Nov 10. Clin Lung Cancer. 2021. PMID: 33358401 Free PMC article. Clinical Trial.
Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy.
Huang CH, Millenson MM, Sherman EJ, Borghaei H, Mintzer DM, Cohen RB, Staddon AP, Seldomridge J, Treat OJ, Tuttle H, Ruth KJ, Langer CJ. Huang CH, et al. Among authors: borghaei h. J Thorac Oncol. 2008 Sep;3(9):1032-8. doi: 10.1097/JTO.0b013e31818307c2. J Thorac Oncol. 2008. PMID: 18758307 Free article. Clinical Trial.
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer.
Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, Hawkins R, Dueland S, Lassen U, Cohen RB. Borghaei H, et al. J Clin Oncol. 2009 Sep 1;27(25):4116-23. doi: 10.1200/JCO.2008.20.2515. Epub 2009 Jul 27. J Clin Oncol. 2009. PMID: 19636016 Free PMC article. Clinical Trial.
Small cell lung cancer.
Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC Jr; National Comprehensive Cancer Network. Kalemkerian GP, et al. Among authors: borghaei h. J Natl Compr Canc Netw. 2011 Oct;9(10):1086-113. doi: 10.6004/jnccn.2011.0092. J Natl Compr Canc Netw. 2011. PMID: 21975911 No abstract available.
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F. Kurzrock R, et al. Among authors: borghaei h. Clin Cancer Res. 2013 Jul 1;19(13):3659-70. doi: 10.1158/1078-0432.CCR-12-3349. Epub 2013 May 9. Clin Cancer Res. 2013. PMID: 23659971 Clinical Trial.
136 results